Article
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Lung cancer (Amsterdam, Netherlands) - 1 Nov 2017
Santoni-Rugiu Eric, Grauslund Morten, Melchior Linea C, Costa Junia C, Sørensen Jens B, Urbanska Edyta M
Abstract excerpt
Patients with epidermal growth factor receptor (EGFR) gene-mutated non-small cell lung cancer (NSCLC) obtain substantial clinical benefit from EGFR tyrosine-kinase inhibitors (TKIs), but will ultimately develop TKI-resistance resulting in median progression-free survival of 9-15 months during first-line TKI-therapy. However, type and timing of TKI-resistance cannot be predicted and several mechanisms may...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.